[Rituximab for the treatment of chronic immune thrombocytopenic purpura]
Pichon Riviere A, Augustovski F, Garcia Marti S, Glujovsky D, Alcaraz A, Lopez A, Bardach A, Ciapponi A, Rey-Ares L
Record ID 32014000307
Spanish
Authors' objectives:
To assess the available evidence on the efficacy, safety and coverage related aspects regarding rituximab use for patients with ITP.
Authors' recommendations:
No studies of good methodological quality were found on rituximab for patients with ITP. Nonetheless, several case series suggest it is effective for the treatment of patients with chronic ITP refractory to standard treatment with an acceptable toxicity profile. Since there is no comparator, part of the effect attributed to rituximab could caused by spontaneous remission, present in 20-50% of these patients during their disease evolution. Lastly, rituximab is considered one of the possible second line treatments in the clinical practice guidelines in different countries worldwide, among which is Argentina.
Details
Project Status:
Completed
Year Published:
2012
URL for published report:
https://www.iecs.org.ar/home-ets/?cod_publicacion=1298&origen_publicacion=publicaciones
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Antibodies, Monoclonal, Murine-Derived
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.